To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.
In this video, Trinity J. Bivalacqua, MD, PhD, presents the case of a 63-year-old man with history of carcinoma in situ found to have low-grade Ta non-muscle invasive bladder cancer.
Based on recent developments with blue light cystoscopy, the use of white light cystoscopy alone is now considered suboptimal as a diagnostic tool.
Biopsy decreases overall uncertainty, is safe, fairly accurate, relatively inexpensive, and improves shared decision-making with patients.
More evidence is needed before blue light cystoscopy becomes the standard of care for diagnosis and treatment and renders white light cystoscopy obsolete.
Renal mass biopsy provides actionable information, but only under specific circumstances—yet it is an increasingly necessary part of the nuanced patient discussion.
An immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) extended overall survival compared with sunitinib (SUTENT) as first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Agents for bladder cancer, prostate cancer, and stress urinary incontinence are also included in this round-up of pipeline developments.
Patients with bacillus Calmette-Guérin-unresponsive bladder cancer had worse clinical outcomes than patients who relapsed but did not meet BCG-unresponsive criteria, according to results of a retrospective analysis presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
Fluorescent blue light cystoscopy improves 3-year recurrence-free survival rates in patients with recurrent bladder tumors compared to white light cystoscopy, and researchers believe its use should be expanded.